Bioanalytical Testing Services Market Research Report – Forecast to 2027

Global Bioanalytical Testing Services Market Research Report: By Molecule Type (Small Molecule, Large Molecule), By Test Type (Pharmacokinetics, Pharmacodynamics, Bioanalysis, Bioequivalence, Others) - Forecast to 2027

ID: MRFR/LS/5111-CR | October, 2018 | Region : Global

Market Synopsis


As per the assessment by Market Research Future (MRFR), the bioanalytical testing services market is projected to procure a considerable market value while expanding at a CAGR of 12.95% CAGR from 2018 to 2023 (forecast period).


The expanding pharmaceutical sector is anticipated to be a notable cause that can bolster the global bioanalytical testing services market during the projection period. The growing focus on the analytical testing of biologics and biosimilars is expected to make a significant contribution in boosting the bioanalytical testing services market growth during the forecast period. In addition, outsourcing of R&D to contract research organizations (CROs) is predicted to make significant participation in augmenting the bioanalytical testing services market revenue.


Impact of COVID-19


The outbreak of COVID-19 has resulted in a rise in government initiatives to control the spread which is projected to strengthen the market. The demand for bioanalytical assessment is anticipated to make a significant contribution in supporting the global bioanalytical testing services market.


Market Overview


The growing demand to cure chronic ailments is one of the primary causes projected to steer the market expansion during the assessment tenure. Furthermore, the growing R&D activities biotechnology and pharmaceutical is expected to strengthen the regional market during the review timeframe.


Drivers


Growing Focus on the Analytical Testing of Biologics and Biosimilars to Promote the Market


The increasing focus on the analytical testing of biologics and biosimilars is predicted to develop the global market during the forecast tenure. The on-going development in biologics is anticipated to strengthen the industry growth in the coming tenure. In addition, the growing prevalence of cancer and other chronic ailments are projected to play a crucial role in growing the biopharmaceutical analytical testing services market.


Opportunities


Increasing Adoption of the Quality by Design Approach to Offer Significant Opportunities for Market Expansion


The increasing adoption of Quality by Design (QbD) is likely to give more effective results with reduced time and costs, which is anticipated to offer lucrative opportunities for market expansion during the forecast period.


Restraints


High Expenses Associated with Drug Discovery to Hamper Market


The high costs associated with drug discovery is expected to hamper the market growth during the review period.


Challenges


The Absence of Expertise to Pose a Challenge for Market Expansion


The absence of expertise is expected to be a significant factor that poses a challenge in market expansion during the assessment tenure.


Cumulative Growth Analysis


The market is anticipated to grow significantly during the forecast period owing to the growing focus on the analytical testing of biologics and biosimilars and the on-going R&D in the pharmaceutical and biopharmaceutical sectors. In addition, the developing countries are likely to make a significant contribution in developing the global market.


Market Segmentation


The bioanalytical testing services market is be segmented by molecule type and test type.


By Molecule Type


Based on the molecule type, the global market for bioanalytical testing services is segmented into small and large. The small molecules segment is projected to thrive a CAGR of 11.94% during the assessment tenure due to its benefits against battling chronic diseases. On the other hand, large molecules are likely to register a higher CAGR (14.76%) than its counterpart owing to the large scale advancements in biologics.


By Test Type


Based on the tests-type, the global market for bioanalytical testing services is segmented into pharmacodynamics (P.D.), bioequivalence, pharmacokinetics (P.K.), bioavailability, and others. P.D. is anticipated to acquire a market value of USD 467.25 million by 2023. The growth can be attributed to the testing capability of determining dose concentration-response relationships of drugs. On the other hand, P.K. is projected to acquire the second position by acquiring a 25% market share while expanding at a CAGR of 13.96% during the review timeframe.


Regional Analysis


Americas to Dominate the Global Market for Bioanalytical Testing Services


The Americas is anticipated to dominate the market due to the presence of established players. The prevailing chronic illness among the expanding populace is projected to be another salient cause that can augment the regional market in the coming period. The high-quality standards in the pharmaceuticals and the rapid growth of the biosimilars are expected to boost the market significantly in the assessment tenure.


As per the analysis by MRFR, the expanding patient pool in the Americas are likely to generate the market value of USD 716.73 million by 2023 while expanding at a CAGR of 12.39% over the forecast timeframe. Among all, the U.S. is anticipated to make the most notable contribution in strengthening the regional market.


APAC to Expand Owing to the Presence of CROs


APAC is anticipated to proliferate during the forecast period owing to the presence of CROs in India and China. As per the assessment, India is likely to be a lucrative market owing to low production costs. The expanding patient pool and the rising R&D are likely to be other salient factors that can augment the regional market during the forecast period. In addition, the increasing outsourcing of drug discovery services to Asian CROs is projected to be another salient cause that can bolster the regional market.


Europe to Expand at a CAGR of 12.95% during the Forecast Period


As per the assessment, Europe is expected to expand at a CAGR of 12.94% over the forecast period owing to the increasing demand for bioanalytical services. The on-going R&D and clinical trials in bioanalytical are other considerable causes that can develop the regional market during the assessment period.


MEA to Witness Sluggish Growth


MEA is anticipated to display a sluggish growth owing to the lack of awareness and underdeveloped healthcare infrastructure. However, the market can expand in the coming period due to the increasing contribution of the Middle East countries owing to their economic stability.


Competitive Landscape


The market is projected to display intense competition due to the growing mergers & acquisitions, product portfolio expansions, and growing initiatives towards innovation.


Key Players Profiled in the Report



  • Toxikon (U.S.)

  • Intertek Group plc (U.K.)

  • Charles River Laboratories, Inc. (U.S.)

  • SGS SA (Switzerland)

  • WuXi AppTec (U.S.)

  • Pharmaceutical Product Development (U.S.)

  • LLC (U.S.)

  • Covance, Inc. (U.S.)

  • ICON plc (Ireland)

  • Pace Analytical Services

  • inVentiv Health (U.S.)

  • Laboratory Corporation of America Holdings (U.S.)


Recent Development



  • November 2020- Eurofins, an international group of laboratories headquartered in Luxembourg, announced the acquisition of Taiyo Techno Research, a Japan-based laboratory that specializes in asbestos testing.

  • December 2020- The leading distributors of test kits and systems for laboratory research, Eurofins Technologies has introduced a new lateral flow device product line for detecting allergen in packaged food products. The device is called SENSIStrip Allergen


Segmentation Table


Bioanalytical Testing Services Market, By Molecule Type



  • Small

  • Large


Bioanalytical Testing Services Market, By Test Type



  • Pharmacodynamics (P.D.)

  • Bioequivalence

  • Pharmacokinetics (P.K.)

  • Bioavailability                          

Bioanalytical Testing Services Market – Summary


Advanced technologies have helped healthcare evolve by giving it accessories for better research and development. Bioanalytical testing services is a byproduct of that technological transformation. The method is required to describe the quantitative measurement of a compound and its metabolite in fluids such as blood, plasma, serum, urine or tissue extracts. It has a multifarious role in developing drugs for both clinical and preclinical stages, and it acts in a holistic way covering from the beginning till the end of the procedure. The global bioanalytical testing services market is expected to reach a valuation of USD 1867.30 million by 2023 with an impressive CAGR of 12.95% during the forecast period (2018-2023). Market Research Future’s detailed research on the same includes a thorough analysis of segments and triggers that would set the market on the right course.


The pharmaceutical industry across the world is experiencing a boom due to the demand generated by the healthcare sector for treatments regarding chronic diseases. Furthermore, research & development is spurring the production of biopharmaceutical drugs, and many of them are waiting in the pipeline only to get proper approval. Both chronic and infectious diseases are pushing the boundary for bioanalytical testing services market further away by giving the market enough scope to develop and launch new medicines.


However, these drugs, owing to extensive research associated with it, are expensive. The entire production procedure incurs heavy cost which resultantly, increases the final cost of the medicine which can be a market deterrent. But their ability to cure people of their diseases can steer the bioanalytical testing services market away from any long-lasting adverse impact.


Segmentation:


By molecule type, the bioanalytical testing services market can be segmented into small molecule and large molecule. Small molecule segment is expected to reach USD 1167.23 million mark from USD 663.99 million by 2023 at CAGR 11.94% during the forecast period. However, large molecule segment to have the fastest CAGR of 14.76% during the review period.


By test type, the bioanalytical testing services market includes pharmacokinetic (PK), pharmacodynamics (PD), bioavailability, bioequivalence, and others. PK segment to scale valuation of USD 757.61 million valuation by 2023 from a valuation of USD 351.12 million with the highest CAGR of 13.86% during the assessment period. PD can record the second fastest CAGR of 13.06% during the review period.


Regional Analysis:


Region-specific analysis of the bioanalytical testing services market the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).


The Americas lead the market while boasting of superior infrastructure and substantial investment in research & development programs. The market is all set to grow from USD 399.77 million in 2018 to a valuation of USD 716.73 million by 2023 with a CAGR of 12.39% during the forecast period.


Europe can assume the second spot with USD 585.61 million market valuation by 2023 with a CAGR of 12.94% during the forecast period. Its growth factors are mostly similar to that of the Americas. However, the APAC is on the right course of progress with China and India leading from the front. The bioanalytical testing services market in the region is expected to scale valuation of USD 435.05 million with the highest CAGR of 14.32% during the forecast period. Low manufacturing and labor cost, and European and American market giants showing interest in the region in terms of business transaction is a signifier of further growth.


The MEA market can only climb up to USD 129.92 million. But its CAGR can be impressive. With 11.76% CAGR, it is showing sign of reformation.


Market Insight:


Significant players proving their worth in the sector are Pharmaceutical Product Development (U.S.), WuXi AppTec (U.S.), ICON plc (Ireland), Covance, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), Charles River Laboratories, Inc. (U.S.), inVentiv Health (U.S.), SGS SA (Switzerland), Toxikon (U.S.), Intertek Group plc (U.K.), Pace Analytical Services, LLC (U.S.), and others. Charles River, with 23.21% market share is currently leading the market followed by Covance Inc. (12.10%).


Major companies rely on strategic developments such as merger, acquisition, collaboration, expansion, new product launch, and others. For instance, in March 2018, Pharmaceutical Product Development recently expanded their testing capacity in Middleton, Wisconsin. WuXi Apptec expanded their drug development testing services in the U.S. and is planning to build a new research & development center in Shanghai.

1 Report Prologue

2 Introduction

2.1 Definition 15

2.2 Scope of the Study 15

2.3 Research Objective 15

2.4 Assumptions & Limitations 15

2.4.1 Assumptions 15

2.4.2 Limitations 15

2.5 Market Structure 16

3 Research Methodology

3.1 Primary Research Methodology 18

3.2 Secondary Research Methodology 19

3.3 Market Size Estimation 20

3.4 Forecast Model 20

4 Market Dynamics

4.1 Introduction 22

4.2 Drivers 22

4.2.1 Growing pharmaceutical industry 22

4.2.2 Rising biopharmaceutical drugs in the pipeline 23

4.2.3 Increasing prevalence of cancer and other infectious diseases 23

4.3 Restraints 23

4.3.1 High cost of drug discovery 23

4.4 Opportunity 23

4.4.1 Entering untapped markets 23

5 Market Factor Analysis

5.1 Porter’s Five Forces Model 25

5.1.1 Bargaining Power of Suppliers 25

5.1.2 Bargaining Power of Buyers 25

5.1.3 Threat of New Entrants 26

5.1.4 Threat of Substitutes 26

5.1.5 Intensity of Rivalry 26

5.2 Value Chain Analysis 27

5.2.1 Drug Discovery/Research 27

5.2.2 Clinical and Preclinical Trials 27

5.2.3 Manufacturing 27

5.2.4 Sales and Distribution 28

6 Bioanalytical Testing Services Market, by Molecule Type

6.1 Introduction 30

6.2 Small Molecule 31

6.2.1 Generics 32

6.2.2 Proprietary 32

6.3 Large Molecule 33

6.3.1 Biomarkers 34

6.3.2 Vaccines 34

6.3.3 Biosimilars 34

7 Bioanalytical Testing Services Market, by Test Type

7.1 Introduction 36

7.1.1 Pharmacokinetics (PK) 37

7.1.2 Pharmacodynamics (PD) 37

7.1.3 Bioanalysis (BA) 38

7.1.4 Bioequivalence (BE) 38

8 Global Bioanalytical Testing Services Market, by Region

8.1 Introduction 40

8.2 Americas 42

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.2.1 North America 44

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.2.1.1 U.S. 46

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.2.1.2 Canada 47

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.2.2 South America 49

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.3 Europe 51

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.3.1 Western Europe 53

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.3.1.1 Germany 55

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.3.1.2 France 56

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.3.1.3 U.K. 58

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.3.1.4 Italy 59

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.3.1.5 Spain 61

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.3.1.6 Rest of Western Europe 62

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.3.1.7 Eastern Europe 64

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.4 Asia Pacific 66

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.4.1 Japan 68

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.4.2 China 69

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.4.3 India 71

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.4.4 Australia 72

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.4.5 Republic of Korea 74

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.4.6 Rest of Asia Pacific 75

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.5 Middle East & Africa 77

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.5.1 Middle East 79

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

8.5.2 Africa 80

Bioanalytical Testing Services Market, by Molecule Type

Bioanalytical Testing Services Market, by Test Type

9 Company Landscape

9.1 Company Share Analysis 83

10 Company Profiles

10.1 Pharmaceutical Product Development, LLC (PPD) 85

10.1.1 Company Overview 85

10.1.2 Financial Overview 85

10.1.3 Products Offering 85

10.1.4 Key Developments 85

10.1.5 SWOT Analysis 86

10.1.6 Key Strategy 86

10.2 WuXi AppTec 87

10.2.1 Company Overview 87

10.2.2 Financial Overview 87

10.2.3 Products Offering 87

10.2.4 Key Developments 87

10.2.5 SWOT Analysis 88

10.2.6 Key Strategy 88

10.3 ICON plc 89

10.3.1 Company Overview 89

10.3.2 Financial Overview 89

10.3.3 Products Offering 90

10.3.4 Key Developments 90

10.3.5 SWOT Analysis 90

10.3.6 Key Strategy 91

10.4 Covance, Inc. 92

10.4.1 Company Overview 92

10.4.2 Products Offering 92

10.4.3 Financial Overview 92

10.4.4 Key Developments 92

10.4.5 SWOT Analysis 93

10.4.6 Key Strategy 93

10.5 Laboratory Corporation of America Holdings 94

10.5.1 Company Overview 94

10.5.2 Financial Overview 94

10.5.3 Key Developments 95

10.5.4 SWOT Analysis 95

10.5.5 Key Strategy 95

10.6 Charles River Laboratories International, Inc. 96

10.6.1 Company Overview 96

10.6.2 Financial Overview 96

10.6.3 Products Offering 97

10.6.4 Key Developments 97

10.6.5 SWOT Analysis 97

10.6.6 Key Strategy 97

10.7 inVentiv Health 98

10.7.1 Company Overview 98

10.7.2 Financial Overview 98

10.7.3 Products Offering 99

10.7.4 Key Developments 99

10.7.5 SWOT Analysis 99

10.7.6 Key Strategy 99

10.8 SGS SA 100

10.8.1 Company Overview 100

10.8.2 Financial Overview 100

10.8.3 Products Offering 101

10.8.4 Key Developments 101

10.8.5 SWOT Analysis 101

10.8.6 Key Strategy 101


10.9 Toxikon 102

10.9.1 Company Overview 102

10.9.2 Financial Overview 102

10.9.3 Products Offering 102

10.9.4 Financial Overview 102

10.9.5 Key Developments 102

10.9.6 SWOT Analysis 103

10.9.7 Key Strategy 103

10.10 Intertek Group plc 104

10.10.1 Company Overview 104

10.10.2 Financial Overview 104

10.10.3 Products Offering 105

10.10.4 Key Developments 105

10.10.5 SWOT Analysis 105

10.10.6 Key Strategy 106

10.11 Pace Analytical Services, LLC 107

10.11.1 Company Overview 107

10.11.2 Products Offering 107

10.11.3 Financial Overview 107

10.11.4 Key Developments 107

10.11.5 SWOT Analysis* 107

10.11.6 Key Strategy 107

11 Appendix 108

11.1 Discussion Blue Print 109

11.2 References 110


11 List of Tables

TABLE 1 PRIMARY INTERVIEWS 19

TABLE 2 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE, 2020–2027 (USD MILLION) 30

TABLE 3 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET, FOR SMALL MOLECULE BY DRUG TYPE, 2020–2027 (USD MILLION) 31

TABLE 4 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY REGION, 2020–2027 (USD MILLION) 31

TABLE 5 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET FOR GENERICS, BY REGION, 2020–2027 (USD MILLION) 32

TABLE 6 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET FOR PROPRIETARY, BY REGION, 2020–2027 (USD MILLION) 32

TABLE 7 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET, FOR LARGE MOLECULE BY TYPE, 2020–2027 (USD MILLION) 33

TABLE 8 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY REGION, 2020–2027 (USD MILLION) 33

TABLE 9 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET FOR BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 10 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET FOR VACCINES, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 11 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 12 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 36

TABLE 13 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET FOR PK, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 14 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET FOR PD, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 15 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET FOR BA, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 16 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET FOR BE, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 17 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET, BY REGION 2020-2027 (USD MILLION) 41

TABLE 18 AMERICAS BIOANALYTICAL TESTING SERVICES MARKET, BY REGION 2020-2027 (USD MILLION) 42

TABLE 19 AMERICAS BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 42

TABLE 20 AMERICAS BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 43

TABLE 21 AMERICAS BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 43

TABLE 22 AMERICAS BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 43

TABLE 23 NORTH AMERICA BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2020-2027 (USD MILLION) 44

TABLE 24 NORTH AMERICA BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 44

TABLE 25 NORTH AMERICA BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE

2020-2027 (USD MILLION) 45

TABLE 26 NORTH AMERICA BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 45

TABLE 27 NORTH AMERICA BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 45

TABLE 28 U.S. BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 46

TABLE 29 U.S. BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 46

TABLE 30 U.S. BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 46

TABLE 31 U.S. BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 47

TABLE 32 CANADA BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 47

TABLE 33 CANADA BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 47

TABLE 34 CANADA BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 48

TABLE 35 CANADA BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 48

TABLE 36 SOUTH AMERICA BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 49

TABLE 37 SOUTH AMERICA BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE

2020-2027 (USD MILLION) 49

TABLE 38 SOUTH AMERICA BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 49

TABLE 39 SOUTH AMERICA BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 50

TABLE 40 EUROPE BIOANALYTICAL TESTING SERVICES MARKET, BY REGION 2020-2027 (USD MILLION) 51

TABLE 41 EUROPE BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 51

TABLE 42 EUROPE BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 52

TABLE 43 EUROPE BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 52

TABLE 44 EUROPE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 52

TABLE 45 WESTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2020-2027 (USD MILLION) 53

TABLE 46 WESTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 53

TABLE 47 WESTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE

2020-2027 (USD MILLION) 54

TABLE 48 WESTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 54

TABLE 49 WESTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 54

TABLE 50 GERMANY BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 55

TABLE 51 GERMANY BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 55

TABLE 52 GERMANY BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 55

TABLE 53 GERMANY BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 56

TABLE 54 FRANCE BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 56

TABLE 55 FRANCE BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 56

TABLE 56 FRANCE BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 57

TABLE 57 FRANCE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 57

TABLE 58 U.K. BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 58

TABLE 59 U.K. BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 58

TABLE 60 U.K. BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 58

TABLE 61 U.K. BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 59

TABLE 62 ITALY BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 59

TABLE 63 ITALY BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 59

TABLE 64 ITALY BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 60

TABLE 65 ITALY BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 60

TABLE 66 SPAIN BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 61

TABLE 67 SPAIN BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 61

TABLE 68 SPAIN BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 61

TABLE 69 SPAIN BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 62

TABLE 70 REST OF WESTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 62

TABLE 71 REST OF WESTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE

2020-2027 (USD MILLION) 62

TABLE 72 REST OF WESTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE

2020-2027 (USD MILLION) 63

TABLE 73 REST OF WESTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 63

TABLE 74 EASTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 64

TABLE 75 EASTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE

2020-2027 (USD MILLION) 64

TABLE 76 EASTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 64

TABLE 77 EASTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 65

TABLE 78 ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2020-2027 (USD MILLION) 66

TABLE 79 ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 66

TABLE 80 ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE

2020-2027 (USD MILLION) 67

TABLE 81 ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 67

TABLE 82 ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 67

TABLE 83 JAPAN BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 68

TABLE 84 JAPAN BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 68

TABLE 85 JAPAN BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 68

TABLE 86 JAPAN BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 69

TABLE 87 CHINA BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 69

TABLE 88 CHINA BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 69

TABLE 89 CHINA BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 70

TABLE 90 CHINA BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 70

TABLE 91 INDIA BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 71

TABLE 92 INDIA BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 71

TABLE 93 INDIA BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 71

TABLE 94 INDIA BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 72

TABLE 95 AUSTRALIA BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 72

TABLE 96 AUSTRALIA BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 72

TABLE 97 AUSTRALIA BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 73

TABLE 98 AUSTRALIA BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 73

TABLE 99 REPUBLIC OF KOREA BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 74

TABLE 100 REPUBLIC OF KOREA BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE

2020-2027 (USD MILLION) 74

TABLE 101 REPUBLIC OF KOREA BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE

2020-2027 (USD MILLION) 74

TABLE 102 REPUBLIC OF KOREA BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 75

TABLE 103 REST OF ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 75

TABLE 104 REST OF ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE

2020-2027 (USD MILLION) 75

TABLE 105 REST OF ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE

2020-2027 (USD MILLION) 76

TABLE 106 REST OF ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 76

TABLE 107 MIDDLE EAST & AFRICA BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY 2020-2027 (USD MILLION) 77

TABLE 108 MIDDLE EAST & AFRICA BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 77

TABLE 109 MIDDLE EAST & AFRICA BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE

2020-2027 (USD MILLION) 78

TABLE 110 MIDDLE EAST & AFRICA BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE

2020-2027 (USD MILLION) 78

TABLE 111 MIDDLE EAST & AFRICA BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 78

TABLE 112 MIDDLE EAST BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 79

TABLE 113 MIDDLE EAST BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE

2020-2027 (USD MILLION) 79

TABLE 114 MIDDLE EAST BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 79

TABLE 115 MIDDLE EAST BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 80

TABLE 116 AFRICA BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020-2027 (USD MILLION) 80

TABLE 117 AFRICA BIOANALYTICAL TESTING SERVICES MARKET FOR SMALL MOLECULE, BY DRUG TYPE 2020-2027 (USD MILLION) 80

TABLE 118 AFRICA BIOANALYTICAL TESTING SERVICES MARKET FOR LARGE MOLECULE, BY TYPE 2020-2027 (USD MILLION) 81

TABLE 119 AFRICA BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020-2027 (USD MILLION) 81


12 List of Figures

FIGURE 1 MARKET STRUCTURE: GLOBAL BIOANALYTICS TESTING SERVICES MARKET 16

FIGURE 2 TOP-DOWN & BOTTOM-UP APPROACHES 20

FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL BIOANALYTICAL TESTING SERVICES MARKET 22

FIGURE 4 PORTER’S FIVE FORCES MODEL 25

FIGURE 5 VALUE CHAIN: BIOANALYTICAL TESTING SERVICES MARKET 27

FIGURE 6 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET, BY MOLECULE TYPE 2020 & 2027 (USD MILLION) 30

FIGURE 7 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE 2020 & 2027 (USD MILLION) 36

FIGURE 8 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET, BY REGION 2020 & 2027 (USD MILLION) 40

FIGURE 9 AMERICAS BIOANALYTICAL TESTING SERVICES MARKET SHARE, BY REGION 2020 (%) 42

FIGURE 10 NORTH AMERICA BIOANALYTICAL TESTING SERVICES MARKET SHARE, BY COUNTRY 2020 (%) 44

FIGURE 11 EUROPE BIOANALYTICAL TESTING SERVICES MARKET SHARE, BY REGION 2020 (%) 51

FIGURE 12 WESTERN EUROPE BIOANALYTICAL TESTING SERVICES MARKET SHARE, BY COUNTRY 2020 (%) 53

FIGURE 13 ASIA PACIFIC BIOANALYTICAL TESTING SERVICES MARKET SHARE, BY COUNTRY 2020 (%) 66

FIGURE 14 THE MIDDLE EAST & AFRICA VETERINARY ULTRASOUND MARKET SHARE, BY REGION 2020 (%) 77

FIGURE 15 GLOBAL BIOANALYTICAL TESTING SERVICES MARKET, COMPANY SHARE ANALYSIS, 2020 (%) 83

Bioanalytical Testing Services Market

Globally there various players operating in this market. With well-established market in the Americas region major companies have their home in the region and generate maximum market share. These companies have expanded their operating unit in various other regions as well. Moreover, there are other small and medium scale players that generate revenue from local market


The above diagram displays the market share generated by the companies in global bioanalytical testing services market in the year 2017. The major part of the market share is accounted by top four companies with 51.87% share for the global Bioanalytical testing services market. The global Bioanalytical testing services market is led by Charles River with 23.21% of the global market share followed by Covance Inc. with 12.10%, ICON plc for the 3rd sport with 9.77% of the market share and  Syneos Health (inVentiv Health) accounted of 6.79% share.


Charles River is one of the leading players in the field of Bioanalytical testing services. The firm accounted for over 23.21% share in 2017. The major reason for its growth is its wide range of services and products and the wide application areas. Moreover, the firm has been the service provider for over 80% of drugs approved by the FDA. Additionally, the firm has a huge global presence with over 80 facilities in 23 countries.


Covance Inc. contributes to approximately 12.10% of the global bioanalytical testing services market. Covance offers a huge service and product portfolio ranging from bioanalytical and analytical services to safety assessment and drug safety testing. The firm has been ranked number one by various industry surveys. Additionally, the firm has a strong foothold with clients in over 60 countries.


ICON plc accounted for the third spot with 9.77% of the market share. The firm has a huge geographic presence due to its wide range of clinical research support services to biopharmaceutical and medical device companies. The firm has a global network of offices in 37 countries.


Syneos Health (inVentiv Health) acquired the fourth spot with over 6.79% share in the global bioanalytical testing services market. The firm caters to large and small to mid-sized companies in the biopharmaceutical, biotechnology, and medical device industries. Additionally, Syneos Health has bioanalytical laboratories located in Quebec, Canada and Princeton, New Jersey that has extensive experience in method development, validation, and bioanalytical analysis support for both small molecule therapeutics and biologics.